Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes

C. Bolden-Watson, E. Richelson

Research output: Contribution to journalArticle

396 Scopus citations

Abstract

We determined the uptake blockade produced by eight new antidepressant drugs (etoperidone, femoxetine, lofepramine, nefazodone, paroxetine, sertraline, tomoxetine, and venlafaxine), two metabolites of newer antidepressants (desmethylsertraline and norfluoxetine), seven previously reported antidepressants, and carbamazepine. Inhibitor constants (Kis) for uptake blockade were obtained from competitive uptake studies with [3H]norepinephrine, [3H]5-hydroxytryptamine, and [3H]dopamine in rat brain synaptosomes prepared from hippocampus, frontal cortex, and striatum, respectively. Among the newer compounds, tomoxetine (Ki = 0.7 nM) and lofepramine (Ki = 1.9 nM) were potent and selective [3H]norepinephrine uptake blockers; paroxetine (Ki = 0.73 nM), sertraline (Ki = 3.4 nM), and femoxetine (Ki = 22 nM) potently and selectively inhibited [3H]5-hydroxytryptamine uptake. Although none of the drugs was potent for [3H]dopamine uptake blockade, sertraline was the most potent (Ki=260 nM). These data are useful in predicting adverse effects and drug-drug interactions of antidepressants.

Original languageEnglish (US)
Pages (from-to)1023-1029
Number of pages7
JournalLife Sciences
Volume52
Issue number12
DOIs
StatePublished - 1993

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes'. Together they form a unique fingerprint.

  • Cite this